Biopharmaceutical
Pharmaceutical
Medical

Gilead Sciences

$65.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.48 (0.75%) Today
+$0.48 (0.75%) Today

Why Robinhood?

You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!

About

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Employees
11,000
Headquarters
Foster City, California
Founded
1987
Market Cap
83.36B
Price-Earnings Ratio
15.72
Dividend Yield
3.65
Average Volume
7.14M
High Today
$65.75
Low Today
$64.90
Open Price
$65.00
Volume
683.66K
52 Week High
$79.61
52 Week Low
$60.32

Collections

Biopharmaceutical
Pharmaceutical
Medical
Biotechnology
Health
Research And Development
Therapy
Technology

News

Barron's21h

Gilead Sciences Increased Some Drug Prices. Why That’s Good News and Bad News for the Stock.

Text size When it comes to Gilead Sciences’ (GILD) latest round of price increases, there’s good news and bad news, wrote Piper Jaffray. The back story. Gilead has fallen 15% in the trailing 12-month period, and has trailed the market year to date as well, rising 4.5%. Downbeat earnings hurt the shares, while investors are also concerned about some of Gilead’s best-known franchises. Successful treatments like its HIV drug are seeing slowing sales gains, and while there’s still optimism about replacements,...

141
Yahoo Finance23h

YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day

For Immediate Release Chicago, IL – March 18, 2019 – Zacks Equity Research YETI Holdings YETI as the Bull of the Day, Gilead Sciences GILD as the Bear of the Day. In addition, Zacks Equity Research provides analysis on FedEx FDX and Amazon AMZN. Here is a synopsis of all five stocks: Scroll to continue with content Ad Bull of the Day: YETI Holdings designs, markets, and distributes outdoor and recreational products under the popular YETI brand primarily in the U.S. The company’s products are designed m...

199
Yahoo FinanceMar 18

Bear of the Day: Gilead Sciences (GILD)

Gilead Sciences (GILD) is aresearch-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

131

Earnings

$1.44
$1.81
$2.19
$2.56
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 30, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.